ImmuneRegen BioSciences (IRBS.OB) and MPI Research Agreement Aimed at Getting Homspera® to Phase 1 Human Clinical
IR BioSciences Holdings, Inc.’s wholly-owned subsidiary, ImmuneRegen BioSciences, Incorporated®, the development stage biotech firm squarely focused on the adult stem cell compound Homspera® (which boosts the immune system, accelerating the healing of wounds and remediating influenza, and can also be used as a vaccine adjuvant), has teamed up with preclinical contract research organization, MPI Research, in a strategic collaboration agreement aimed at procuring Phase 1 human clinical studies of the amazing new drug Homspera. CEO of ImmuneRegen, Michael Wilhelm, explained that this agreement with MPI enables immediate satisfaction of the FDA-required safety studies, and welcomed the rock-solid “independent validation” of…